BMS Signs a Research Collaboration with DarwinHealth to Discover Novel Cancer Target Initiative

 BMS Signs a Research Collaboration with DarwinHealth to Discover Novel Cancer Target Initiative

Shots:

  • DarwinHealth will receive an upfront and eligible to receive as a commercial milestone, as part of the NCTI collaboration
  • The focus of the collaboration is to identify NCTs across tumor subtypes for different cancer types by using quantitative systems biology-based algorithms, databases, and technologies and leads to the development of drugs with multi-subtype indications
  • Following the NCTs discovery, BMS gets the proprietary information from DarwinHealth in its drug databases, including specific tumor analyses from MRs or MRUMs of distinct tumor subtypes

Click here to­ read full press release/ article | Ref: PRNewswire | Image: BMS

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post